Showing 2271-2280 of 18617 results for "".
Blood Matters: From Inherited Illness to Designer Babies
https://reachmd.com/programs/clinicians-roundtable/blood-matters-from-inherited-illness-to-designer-babies/2989/Blood Matters: From Inherited Illness to Designer Babies is the work of Moscow-based author and journalist, Masha Gessen. Ms. Gessen discusses her book, based in part upon her experience as a carrier of the BRCA gene, with host Dr. Michael Greenberg.Industry and Healthcare: Sorting Out Potential Conflicts
https://reachmd.com/programs/heart-matters/industry-and-healthcare-sorting-out-potential-conflicts/4045/How can individual practitioners interact with industry in a positive, lawful and commendable manner? Are there regulations we can and should put on companies in this arena which fund initiatives such as continuing medical education? Industry certainly plays a major role in health care today, but onATTR-CM Care: Impact of Vutrisiran on Survival and Cardiovascular Events
https://reachmd.com/programs/heart-matters/attr-cm-care-impact-of-vutrisiran-on-survival-and-cardiovascular-events/36144/Even though care for transthyretin amyloid cardiomyopathy (ATTR-CM) has advanced in recent years, this progressive disease is still associated with significant morbidity and mortality. That's why the HELIOS-B trial investigated vutrisiran, an RNA interference therapy, to determine its potential to rFactors Influencing the Selection of Amyloid PET Tests for Alzheimer Disease
https://practicalneurology.com/videos/neurology-in-motion/factors-influencing-the-selection-of-amyloid-pet-tests-for-alzheimer-disease/37135/Suzanne Schindler, MD, PhD, Associate Professor of Neurology at Washington University School of Medicine in St. Louis, discusses key factors influencing the selection of amyloid PET tests for Alzheimer disease.Inherited Heart Diseases
https://reachmd.com/programs/clinicians-roundtable/inherited-heart-diseases/2523/How do we recognize and treat genetic heart disease in the single patient, and beyond? Dr. Elizabeth McNally, cardiologist and world-renowned expert on heart disease genetics speaks with Dr. Bruce Bloom on inherited heart diseases; covering their diagnosis, treatment, and varied prevalence aroundDiagnosis and Treatment of Inherited Heart Diseases
https://reachmd.com/programs/clinicians-roundtable/diagnosis-and-treatment-of-inherited-heart-diseases/2525/Dr. Elizabeth McNally, internationally renowned expert on inherited heart diseases, Professor of Medicine and Human Genetics and Director of both the Institute for Cardiovascular Research and the Cardiovascular Genetics Clinic at the University of Chicago Medical Center joins your host, Dr. Bruce BlThe Psychiatric Impact of OB/GYN Disorders
https://reachmd.com/programs/advances-in-womens-health/the-psychiatric-impact-of-obgyn-disorders/2678/What is the psychological impact on patients faced with difficult obstretic and gynecology-related situations? Dr. Nehama Dresner, associate professor of clinical psychiatry, behavioral sciences, and obstetrics and gynecology at Northwestern University's Feinberg School of Medicine, addresses situatSERENA-6: Assessing Camizestrant’s Impact in HR+/HER2- Breast Cancer
https://reachmd.com/programs/project-oncology/serena-6-assessing-camizestrants-impact-in-hrher2-breast-cancer/36163/The SERENA-6 trial, which was presented at the 2025 ESMO Congress, explores a novel strategy in treating HR+/HER2- advanced breast cancer by switching to camizestrant upon detection of ESR1 mutation prior to disease progression. This approach has been shown to improve progression-free survival and dThe Importance of Diagnosing Dry Eye Disease Early
https://reachmd.com/programs/medical-industry-feature/the-importance-of-diagnosing-dry-eye-disease-early/24201/Here’s a quick review of why a timely diagnosis of dry eye disease is so important and how a treatment option may help address the signs and symptoms.TILplus Score as a Potential Predictive Biomarker in First-Line ICI Therapy for mccRCC
https://reachmd.com/programs/project-oncology/tilplus-score-as-a-potential-predictive-biomarker-in-first-line-ici-therapy-for-mccrcc/33001/Can histopathology help predict response to immunotherapy in metastatic clear cell renal cell carcinoma (mccRCC)? A new retrospective study presented at ASCO 2025 suggests that TILplus—a simple scoring system based on immune infiltrate proximity in H&E-stained metastatic tissue—may serve as a va